April 24, 2020 12:47 PM EDT
FDA+
Coronavirus

FDA warns on safe­ty threat posed by 2 drugs ini­tial­ly backed by Trump for Covid-19 — fol­low­ing an emer­gency use au­tho­riza­tion

John Carroll

Editor & Founder

Two of Pres­i­dent Trump’s ini­tial top picks as near-term ther­a­peu­tic reme­dies for Covid-19 are the sub­ject of an FDA safe­ty warn­ing to­day.

The agency is­sued …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times